Protoveratrine BCAS# 124-97-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 124-97-0 | SDF | Download SDF |
PubChem ID | 222158 | Appearance | Powder |
Formula | C41H63NO15 | M.Wt | 809.9 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Synonyms | Veratetrine;Neoprotoveratrin;Neoprotoveratrine | ||
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | [(1S,2S,6S,9S,10S,11R,12R,13S,14S,15S,16S,17R,18R,19S,22S,23S,25R)-16,17-diacetyloxy-10,12,14,23-tetrahydroxy-6,10,19-trimethyl-13-[(2R)-2-methylbutanoyl]oxy-24-oxa-4-azaheptacyclo[12.12.0.02,11.04,9.015,25.018,23.019,25]hexacosan-22-yl] (2R,3R)-2,3-dihydroxy-2-methylbutanoate | ||
SMILES | CCC(C)C(=O)OC1C(C2C(CN3CC(CCC3C2(C)O)C)C4C1(C5C(C(C6C7(C5(C4)OC6(C(CC7)OC(=O)C(C)(C(C)O)O)O)C)OC(=O)C)OC(=O)C)O)O | ||
Standard InChIKey | BFLXOMFFVWQPAZ-CEEVVQPDSA-N | ||
Standard InChI | InChI=1S/C41H63NO15/c1-10-19(3)34(47)56-33-28(46)27-23(17-42-16-18(2)11-12-25(42)38(27,9)50)24-15-39-32(40(24,33)51)30(54-22(6)45)29(53-21(5)44)31-36(39,7)14-13-26(41(31,52)57-39)55-35(48)37(8,49)20(4)43/h18-20,23-33,43,46,49-52H,10-17H2,1-9H3/t18-,19+,20+,23-,24-,25-,26-,27+,28+,29-,30+,31-,32+,33-,36-,37+,38+,39+,40-,41+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Protoveratrine B Dilution Calculator
Protoveratrine B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.2347 mL | 6.1736 mL | 12.3472 mL | 24.6944 mL | 30.868 mL |
5 mM | 0.2469 mL | 1.2347 mL | 2.4694 mL | 4.9389 mL | 6.1736 mL |
10 mM | 0.1235 mL | 0.6174 mL | 1.2347 mL | 2.4694 mL | 3.0868 mL |
50 mM | 0.0247 mL | 0.1235 mL | 0.2469 mL | 0.4939 mL | 0.6174 mL |
100 mM | 0.0123 mL | 0.0617 mL | 0.1235 mL | 0.2469 mL | 0.3087 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Trichodesmine
Catalog No.:BCN2145
CAS No.:548-90-3
- Gyrophoric acid
Catalog No.:BCN5731
CAS No.:548-89-0
- Galangin
Catalog No.:BCN5730
CAS No.:548-83-4
- Pinobanksin
Catalog No.:BCN5729
CAS No.:548-82-3
- Tectorigenin
Catalog No.:BCN1019
CAS No.:548-77-6
- Irigenin
Catalog No.:BCN3849
CAS No.:548-76-5
- Quercetagetin-7-O-glucoside
Catalog No.:BCN6480
CAS No.:548-75-4
- Crystal Violet
Catalog No.:BCC4772
CAS No.:548-62-9
- Cornin
Catalog No.:BCN5008
CAS No.:548-37-8
- Oxysanguinarine
Catalog No.:BCN8100
CAS No.:548-30-1
- Isolariciresinol
Catalog No.:BCN5727
CAS No.:548-29-8
- Isoginkgetin
Catalog No.:BCN2320
CAS No.:548-19-6
- Daphneolone
Catalog No.:BCN3230
CAS No.:54835-64-2
- Roseoside
Catalog No.:BCN5728
CAS No.:54835-70-0
- Protogracillin(P)
Catalog No.:BCC8352
CAS No.:54848-30-5
- Sanshodiol
Catalog No.:BCN6577
CAS No.:54854-91-0
- PD 334581
Catalog No.:BCC6300
CAS No.:548756-68-9
- Arborinine
Catalog No.:BCN7438
CAS No.:5489-57-6
- Amitriptyline HCl
Catalog No.:BCC5033
CAS No.:549-18-8
- 8-Oxyberberine
Catalog No.:BCN3135
CAS No.:549-21-3
- Quercetin 3-O-beta-D-xylopyranoside
Catalog No.:BCN2851
CAS No.:549-32-6
- beta-Yohimbine
Catalog No.:BCN5733
CAS No.:549-84-8
- Phytolaccagenic acid
Catalog No.:BCN8090
CAS No.:54928-05-1
- Shikalkin
Catalog No.:BCC8359
CAS No.:54952-43-1
Inhibition of some new cardiotonic agents by tetrodotoxin.[Pubmed:2434106]
Arzneimittelforschung. 1986 Oct;36(10):1461-3.
The effects of sulmazole, milrinone and 1,5-dihydro-6-chloro-3-methylimidazo[2,1-b]quinazolone-2 on guinea pig left atria were studied, measuring the force of contraction in the absence and in the presence of 1 x 10(-5) mol/l octahydro-12-(hydroxymethyl)-2-imino-5,9: 7,10a-dimethano-10aH-[1,3]-dioxocino[6,5-d]pyrimidine- 4,7,10, 11,12-pentol (tetrodotoxin, TTX). The dihydropyridine derivative methyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-tri-fluoromethylphenyl) pyridine-5-carboxylate, a Ca2+ agonist, was also tested. Protoveratrine B, which prolongs the Na+ current phase, was inhibited by TTX. Isoprenaline, whose activity is mediated by cyclic adenosine monophosphate and consequently by the increase in slow inward Ca2+ current, was not. TTX antagonized competitively sulmazole, milrinone and the quinazolone drug and reduced only the activity of the dihydropyridine derivative. These results suggest an interference of the new cardiotonic drugs with the fast Na+ channel.